Keywords: Actelion, Opsumit, USA, FDA, PAH, Pulmonary arterial hypertension, Macitentan

Actelion files for US approval of Opsumit for PAH

Article | 23 October 2012

Print This

Europe’s largest biotech company Actelion (SIX: ATLN) said yesterday that it has submitted a New Drug Application with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in